|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.78 HKD | -0.60% |
|
+7.34% | +26.53% |
| 01-15 | WuXi Biologics Shareholder to Sell Shares | MT |
| 01-15 | Wuxi Biologics (Cayman) says Wuxi Biologics Holdings enters block trade agreement with Morgan Stanley | RE |
| Capitalization | 147B 164B 21.08B 18.18B 16.92B 15.75B 29.33B 1,913B 31.55B 195B 76.74B 912B 79.06B 77.43B 3,332B | P/E ratio 2025 * |
32.9x | P/E ratio 2026 * | 29x |
|---|---|---|---|---|---|
| Enterprise value | 140B 157B 20.11B 17.34B 16.14B 15.03B 27.98B 1,825B 30.1B 186B 73.22B 871B 75.43B 73.88B 3,179B | EV / Sales 2025 * |
6.51x | EV / Sales 2026 * | 5.55x |
| Free-Float |
86.37% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | -0.60% | ||
| 1 week | +7.34% | ||
| Current month | +26.53% | ||
| 1 month | +22.25% | ||
| 3 months | +13.14% | ||
| 6 months | +40.57% | ||
| Current year | +26.53% |
| 1 week | 36.6 |  | 40.4 |
| 1 month | 31.1 | | 40.4 |
| Current year | 31.1 | | 40.4 |
| 1 year | 16.2 | | 42.6 |
| 3 years | 10.14 | | 72.5 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 2015-12-31 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 2021-08-22 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-03-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 75 | 2023-05-05 |
William Keller
BRD | Director/Board Member | 77 | 2017-05-16 |
Ge Li
CHM | Chairman | 58 | 2014-01-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 9.62% | 0 M€ | |
| -3.45% | 4.23% | 0 M€ | |
| +1.96% | 2.99% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.60% | +7.34% | +121.49% | -42.68% | 21.08B | |
| -0.49% | 0.00% | +8.75% | +88.27% | 49.24B | |
| +0.71% | +5.27% | +96.79% | +9.03% | 44.64B | |
| +1.35% | -8.27% | +122.62% | +744.25% | 34.43B | |
| +2.76% | +9.16% | -2.62% | -23.88% | 27.35B | |
| +0.97% | +0.14% | +44.75% | -20.98% | 20.89B | |
| -0.74% | -5.17% | +104.56% | +168.59% | 14.29B | |
| +0.72% | -0.55% | +191.39% | - | 14.17B | |
| -1.33% | -13.41% | -10.46% | +271.24% | 13.14B | |
| Average | +0.37% | -0.56% | +75.25% | +149.23% | 26.58B | |
| Weighted average by Cap. | +0.50% | +0.50% | +68.83% | +152.64% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 21.53B 24.09B 3.09B 2.66B 2.48B 2.31B 4.3B 280B 4.62B 28.52B 11.25B 134B 11.59B 11.35B 488B | 25B 27.98B 3.59B 3.09B 2.88B 2.68B 4.99B 325B 5.37B 33.12B 13.06B 155B 13.45B 13.18B 567B |
| Net income | 4.46B 4.99B 640M 552M 514M 478M 890M 58.08B 958M 5.91B 2.33B 27.7B 2.4B 2.35B 101B | 5.06B 5.67B 726M 626M 583M 543M 1.01B 65.91B 1.09B 6.71B 2.64B 31.44B 2.72B 2.67B 115B |
| Net Debt | -6.75B -7.56B -969M -835M -778M -724M -1.35B -87.93B -1.45B -8.95B -3.53B -41.94B -3.63B -3.56B -153B | -8.27B -9.26B -1.19B -1.02B -953M -887M -1.65B -108B -1.78B -10.96B -4.32B -51.39B -4.45B -4.36B -188B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 39.78 $ | -0.60% | 219,334,000 |
| 26-01-15 | 40.02 $ | +0.05% | 30,013,460 |
| 26-01-14 | 40.00 $ | +0.55% | 47,053,090 |
| 26-01-13 | 39.78 $ | +5.85% | 79,031,700 |
| 26-01-12 | 37.58 $ | +1.40% | 54,713,420 |
Delayed Quote Hong Kong S.E., January 16, 2026 at 03:08 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition